Pharming Group N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 15 apr 2009 - 18:23

Statutaire naam Pharming Group N.V.

Titel PHARMING ANNUAL SHAREHOLDER’S MEETING

Bericht Leiden, The Netherlands, April 15, 2009. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) has provided an update on its product, financial and corporate developments during the Annual Meeting of Shareholders (AGM) today. During the meeting, the Company confirmed its strategy to become an international specialty pharmaceutical company. This includes the development of therapeutic products for significant medical needs in orphan disease indications and for indications with serious unmet medical needs in larger markets in a second phase, Rhucin being the first example. Pharming will submit the dossier for the European Marketing Authorisation Application of Rhucin® for acute attacks of Hereditary Angioedema in September 2009. In addition, the product is under development for additional indications in the field of kidney transplantations. Products under development following this same strategy are Prodarsan®, expected to enter full clinical development later this year and recombinant human fibrinogen, currently in pre-clinical development. While the current liquidity position of Pharming is sufficient for its operational development efforts into 2010, the Company continues to look at additional financing opportunities to further improve its financial position. Today’s announcement of the standby equity agreement with Yorkville Advisors is a first example of such financing activities. With the earlier announced agreements with its bondholders on the cancellation of convertible bonds at favourable terms for the Company and the two milestone payments of € 10 million in total expected from Aslan later this year, Pharming is confident about its prospects for 2009 and 2010. Following the appointment of Mr. Sijmen de Vries, Mr Francis J. Pinto stayed on as Non-Executive Chairman of the Management Board to ensure a smooth transition. He retires as of today. As part of the transition plan, a number of task forces were put in place, which

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

200904150000000019_090415 AGM ENG.pdf (opens in a new window)

Datum laatste update: 22 januari 2026